|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Szöllösi J, Balázs M, Feuerstein BG, Benz
CC and Waldman FM: ERBB-2 (HER2/neu) gene copy number, p185HER-2
overexpression, and intratumor heterogeneity in human breast
cancer. Cancer Res. 55:5400–5407. 1995.PubMed/NCBI
|
|
4
|
Ramieri MT, Murari R, Botti C, Pica E,
Zotti G and Alo PL: Detection of HER2 amplification using the SISH
technique in breast, colon, prostate, lung and ovarian carcinoma.
Anticancer Res. 30:1287–1292. 2010.PubMed/NCBI
|
|
5
|
Hofmann M, Stoss O, Shi D, Büttner R, van
de Vijver M, Kim W, Ochiai A, Rüschoff J and Henkel T: Assessment
of a HER2 scoring system for gastric cancer: Results from a
validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shitara K, Yatabe Y, Matsuo K, Sugano M,
Kondo C, Takahari D, Ura T, Tajika M, Ito S and Muro K: Prognosis
of patients with advanced gastric cancer by HER2 status and
trastuzumab treatment. Gastric Cancer. 16:261–267. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
An E, Ock CY, Kim TY, Lee KH, Han SW, Im
SA, Kim TY, Liao WL, Cecchi F, Blackler A, et al: Quantitative
proteomic analysis of HER2 expression in the selection of gastric
cancer patients for trastuzumab treatment. Ann Oncol. 28:110–115.
2017.PubMed/NCBI
|
|
8
|
Zhou R, Copeland TD, Kromer LF and Schulz
NT: Isolation and characterization of Bsk, a growth factor
receptor-like tyrosine kinase associated with the limbic system. J
Neurosci Res. 37:129–143. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Symonds AC, King CE, Bartlett CA, Sauvé Y,
Lund RD, Beazley LD, Dunlop SA and Rodger J: EphA5 and ephrin-A2
expression during optic nerve regeneration: A ‘two-edged sword’.
Eur J Neurosci. 25:744–752. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Washburn CP, Cooper MA and Zhou R:
Expression of the tyrosine kinase receptor EphA5 and its ligand
ephrin-A5 during mouse spinal cord development. Neurosci Bull.
23:249–255. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cooper MA, Crockett DP, Nowakowski RS,
Gale NW and Zhou R: Distribution of EphA5 receptor protein in the
developing and adult mouse nervous system. J Comp Neurol.
514:310–328. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Unified nomenclature for Eph family
receptors and their ligands, the ephrins. Eph nomenclature
committee. Cell. 90:403–404. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang J, Kataoka H, Suzuki M, Sato N,
Nakamura R, Tao H, Maruyama K, Isogaki J, Kanaoka S, Ihara M, et
al: Downregulation of EphA7 by hypermethylation in colorectal
cancer. Oncogene. 24:5637–5647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dawson DW, Hong JS, Shen RR, French SW,
Troke JJ, Wu YZ, Chen SS, Gui D, Regelson M, Marahrens Y, et al:
Global DNA methylation profiling reveals silencing of a secreted
form of Epha7 in mouse and human germinal center B-cell lymphomas.
Oncogene. 26:4243–4252. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen P, Huang Y, Zhang B, Wang Q and Bai
P: EphA2 enhances the proliferation and invasion ability of LNCaP
prostate cancer cells. Oncol Lett. 8:41–46. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang H, Wen J, Wang H, Guo Q, Shi S, Shi
Q, Zhou X, Liu Q, Lu G and Wang J: Loss of expression of EphB1
protein in serous carcinoma of ovary associated with metastasis and
poor survival. Int J Clin Exp Pathol. 7:313–321. 2013.PubMed/NCBI
|
|
17
|
Wu R, Wang H, Wang J, Wang P, Huang F, Xie
B, Zhao Y, Li S and Zhou J: EphA3, induced by PC-1/PrLZ,
contributes to the malignant progression of prostate cancer. Oncol
Rep. 32:2657–2665. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Staquicini FI, Qian MD, Salameh A, Dobroff
AS, Edwards JK, Cimino DF, Moeller BJ, Kelly P, Nunez MI, Tang X,
et al: Receptor tyrosine kinase EphA5 is a functional molecular
target in human lung cancer. J Biol Chem. 290:7345–7359. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fu DY, Wang ZM, Wang BL, Chen L, Yang WT,
Shen ZZ, Huang W and Shao ZM: Frequent epigenetic inactivation of
the receptor tyrosine kinase EphA5 by promoter methylation in human
breast cancer. Hum Pathol. 41:48–58. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li S, Zhu Y, Ma C, Qiu Z, Zhang X, Kang Z,
Wu Z, Wang H, Xu X, Zhang H, et al: Downregulation of EphA5 by
promoter methylation in human prostate cancer. BMC Cancer.
15:182015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen X, Wang X, Wei X and Wang J: EphA5
protein, a potential marker for distinguishing histological grade
and prognosis in ovarian serous carcinoma. J Ovarian Res. 9:832016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gu S, Feng J, Jin Q, Wang W and Zhang S:
Reduced expression of EphA5 is associated with lymph node
metastasis, advanced TNM stage, and poor prognosis in colorectal
carcinoma. Histol Histopathol. 32:491–497. 2017.PubMed/NCBI
|
|
23
|
Aaltonen LA and Hamilton SR: Pathology and
Genetics of Tumors of the Digestive System. The
Tumor-Node-Metastasis (TNM) System of the World Health Organization
Classification of Tumors. IARC Press; Lyon: 2000
|
|
24
|
Laurén P: Pekka Laurén and histological
classification of gastric carcinoma. Interview and comment by Timo
J Nevalainen. Gut. 62:1230–1231. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Woo CG, Ho WJ, Park YS, Park SR, Ryu MH,
Jung HY and Kang YK: A potential pitfall in evaluating HER2
immunohistochemistry for gastric signet ring cell carcinomas.
Pathology. 49:38–43. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cabrero M, Yu Y, Verma A, Yang H, Colla S,
Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, et al:
Downregulation of protection of telomeres 1 expression in
myelodysplastic syndromes with 7q deletion. Br J Haematol.
173:161–165. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Coccaro N, Zagaria A, Orsini P, Anelli L,
Tota G, Casieri P, Impera L, Minervini A, Minervini CF, Cumbo C, et
al: RARA and RARG gene downregulation associated with EZH2 mutation
in acute promyelocytic-like morphology leukemia. Hum Pathol.
80:82–86. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shuai F, Wang B and Dong S: MicroRNA-204
inhibits the growth and motility of colorectal cancer cells by
downregulation of CXCL8. Oncol Res. 26:1295–1305. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ulker D, Ersoy YE, Gucin Z, Muslumanoglu M
and Buyru N: Downregulation of SCARA5 may contribute to breast
cancer via promoter hypermethylation. Gene. 673:102–106. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ye F, Chen C, Qin J, Liu J and Zheng C:
Genetic profiling reveals an alarming rate of cross-contamination
among human cell lines used in China. FASEB J. 29:4268–4272. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chua TC and Merrett ND: Clinicopathologic
factors associated with HER2-positive gastric cancer and its impact
on survival outcomes-a systematic review. Int J Cancer.
130:2845–2856. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Youngblood VM, Kim LC, Edwards DN, Hwang
Y, Santapuram PR, Stirdivant SM, Lu P, Ye F, Brantley-Sieders DM
and Chen J: The Ephrin-A1/EPHA2 signaling axis regulates glutamine
metabolism in HER2-positive breast cancer. Cancer Res.
76:1825–1836. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang G, Chen S, Wang D, Wang R, Lin L,
Chen S, Wang L and Huang Q: High Ki67 expression has prognostic
value in surgically-resected T3 gastric adenocarcinoma. Clin Lab.
62:141–153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yagi T, Inoue N, Yanai A, Murase K,
Imamura M, Miyagawa Y, Enomoto Y, Nishimukai A, Takatsuka Y, Hirota
S, et al: Prognostic significance of geminin expression levels in
Ki67-high subset of estrogen receptor-positive and HER2-negative
breast cancers. Breast Cancer. 23:224–230. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Min KW, Kim DH, Son BK, Kim DH, Kim EK,
Seo J, Ahn SB, Jo YJ, Park YS and Ha J: A High Ki67/BCL2 index
could predict lower disease-free and overall survival in
intestinal-type gastric cancer. Eur Surg Res. 58:158–168. 2017.
View Article : Google Scholar : PubMed/NCBI
|
